-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Benzinga·05/29/2026 16:52:06
Listen to the news
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $43 to $45.